- With Corindus, Siemens Healthineers aims to drive cardiovascular interventions with robotic assistance in India
- The robot facilitates smart procedural automation, which can enable performing complex interventional cases with shorter time and better clinical outcomes
- Key challenges of limited availability of skilled manpower and clinical infrastructure for minimally invasive procedures in many regions in India can be addressed with this technology
Siemens Healthineers has now added in its portfolio Corindus CorPath GRX, the only FDA cleared and CE certified Robotic System, for Coronary and Peripheral Vascular Interventions in India.
With state-of-art technology, the company has opened a new field for Advanced Therapies business, tapping into adjacent growth markets with great potential for the future.
Robotic systems for minimally invasive procedures help doctors to precisely control guide catheters, guide wires, balloon or stent implants via integrated imaging. The physician does not have to stand at the angiography table as usual but can control the procedure with a separate controlling module and is therefore protected from radiation. Recent studies have shown that the CorPath GRX robot system facilitates upto 20% reduction in radiation dose to patients.
Cardiovascular diseases (CVDs), especially coronary heart disease (CHD), have assumed epidemic proportions worldwide. India is fast becoming the world's capital of coronary heart disease and diabetes, a leading cause of mortality in India. One in 4 deaths in India are because of CVDs with ischemic heart disease and stroke responsible for more than 80% of this burden, due to increasing prevalence of CVD risk factors including lifestyle changes.
The robotic cardiovascular interventions can aid significantly in this case, by contributing to cardiovascular medical conditions like heart diseases, where the ideal treatment include complex procedures in the coronary arteries by specialized medical professionals. The smart procedural automation can enable performing complex interventional cases in shorter time, with precision, and with better clinical outcomes.
Adoption of robotics in surgical intervention will provide an enormous impetus to the Indian healthcare sector. Possbilities of remote treatment in the near future (currently under approval) could address the key geographical challenges of limited availability of specialists and corresponding clinical facilities for minimally invasive procedures in many regions.
With Corindus technology, Siemens Healthineers is well-positioned to be the leading player in the field of robotic vascular interventions.
“Together with our strong portfolio in medical imaging, digitalization and artificial intelligence, we are creating significant synergies to advance therapy outcomes. The interplay of protection, precision and standardization through robotic-assisted interventions will allow the cardiologists to perform complex procedures faster and better. This will allow specialists to improve procedural quality and expand precision medicine; thereby improving clinical outcomes for the patient.”, said Sanjay David, Head of Advanced Therapies, Siemens Healthineers, India.
Siemens Healthineers products make minimally invasive treatment possible by using high-quality imaging before and during medical interventions, this is now complemented by protection, precision and standardization through robotic-assisted interventions.
Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care to patients.
In fiscal 2020, which ended on September 30, 2020, Siemens Healthineers, which has approximately 54,000 employees worldwide, generated revenue of €14.5 billion and adjusted EBIT of €2.2 billion. Further information is available at www.siemens-healthineers.co.in
Contact for journalists
Pranav Patil, Siemens Healthineers, India
Email: pranav.patil@siemens-healthineers.com
Khushboo Bhadani, Siemens Healthineers, India
Email: khushboo.bhadani@siemens-healthineers.com
Mobile: +91 7208185374